Vaccine AdvisorCDC Issues Updated Guidance on Pentavalent Meningococcal Vaccine Options

The CDC authorized pentavalent meningococcal vaccine (MenABCWY) covering all five disease-causing serogroups in single injection, eliminating need for separate MenACWY and MenB vaccines. Clinical trials in 10-25 year-olds showed comparable immune responses to existing vaccines with no new safety concerns.

📋 CLINICAL CONSIDERATIONS

• Vaccine meets noninferiority criteria for all five serogroups (A, B, C, W, Y) based on serum bactericidal antibody responses in adolescents aged 10-25 years.
• Single-injection option reduces visit burden for routine adolescent vaccination and high-risk populations including complement deficiencies, asplenia, and outbreak exposures.
• Pentavalent vaccine is manufacturer-specific and provides option only for patients receiving GSK’s MenB-4C vaccine (Bexsero) for other doses due to lack of interchangeability.
• Existing booster schedules remain unchanged based on age and ongoing risk status; trials did not assess effectiveness against invasive disease or duration of protection.

💉 PRACTICE APPLICATIONS

• Offer pentavalent vaccine to adolescents due for both MenACWY and MenB vaccination to consolidate into single visit
• Review current meningococcal vaccine inventory to determine if GSK product alignment supports pentavalent adoption in your practice
• Counsel families that single-injection option maintains same protection as two-vaccine series with comparable mild injection-site reactions
• Document which manufacturer’s serogroup B vaccine patient receives to ensure series completion compatibility

More on Vaccines/Immunizations